Benchmarking fragmentation-derived artificial cfDNA reference standards
An important step toward clinical implementation of (epi-)genomic assays on liquid biopsies is their validation on identical samples within and across laboratories. For these validation studies, there is a need for cell-free DNA (cfDNA) samples with defined tumor fractions and (epi-)genomic aberrations. However, the amount of circulating cfDNA isolated from patient samples is often limited,…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.